Literatur

1. Cortes J et al. A phase 2 trial of ponatinib in Philadelphia chromosome–positive leukemias. N Engl J Med 2013; 369: 1783-96.

2. Müller MC et al. Achieving early landmark response is predictive of outcomes in heavily pretreated patients with chronic phase chronic myeloid leukemia (CP-CML) treated with ponatinib. ASH 2014, Abstract #518.